Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...

Resistant to the staff and distant from his friendly roommate, Mortensen soon clashes with seemingly gentle resident Dave Crealy who secretly terrorizes the home with a sadistic game called "The Rule ...

AbbVie stock (NYSE:ABBV) has exhibited considerable rally potential, having once achieved over a 50% increase in less than two months in 2020. Furthermore, the stock has undergone seven rallies ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...

AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV’s valuation remains attractive; a 14.4x FY 2027 multiple is ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on AbbVie to $269 from $261 with an Overweight rating on the shares ...

Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...

AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. The JEPQ ETF employs a covered-call ...

AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected. AbbVie's valuation and dividend program seal the deal.

High induction doses of risankizumab — at double and quadruple the approved 150 mg dose — produced rapid and durable skin clearance in patients with moderate-to-severe plaque psoriasis while ...